Baxter International Inc

Explore Baxter International’s legal woes, debt strategy and investor fallout—why the stock’s tumble may signal deeper governance and financial risks.

Baxter International Inc. has trimmed its 2025 financial outlook due to disappointing quarterly earnings and the lingering effects of Hurricane Helene, leading to a decline in its stock price.

Baxter International Inc. has trimmed its 2025 financial outlook due to challenges from Hurricane Helene, which damaged a key manufacturing facility and disrupted its supply chain.

Baxter International Inc. is poised to capitalize on the growing biosurgery and hemostats markets, projected to reach $21.59 billion and $4.25 billion by 2030 and 2031, respectively.

Baxter International Inc. has boosted its fiscal year 2025 outlook after a strong Q1 performance, exceeding earnings estimates and prompting a positive market reaction.

Baxter International Inc. is at a critical juncture as it prepares to release its Q1 earnings, with investors eagerly awaiting signs of growth and stability amidst a volatile market and intense industry competition.